Oncogenic states dictate the prognostic and predictive connotations of intratumoral immune response

Background An immune active cancer phenotype typified by a T helper 1 (Th-1) immune response has been associated with increased responsiveness to immunotherapy and favorable prognosis in some but not all cancer types. The reason of this differential prognostic connotation remains unknown. Methods To explore the contextual prognostic value of cancer immune phenotypes, we applied a multimodal pan-cancer analysis among 31 different histologies (9282 patients), encompassing immune and oncogenic transcriptomic analysis, mutational and neoantigen load and copy number variations. Results We demonstrated that the favorable prognostic connotation conferred by the presence of a Th-1 immune response was abolished in tumors displaying specific tumor-cell intrinsic attributes such as high transforming growth factor-beta (TGF-β) signaling and low proliferation capacity. This observation was independent of mutation rate. We validated this observation in the context of immune checkpoint inhibition. WNT-β catenin, barrier molecules, Notch, hedgehog, mismatch repair, telomerase activity and AMPK signaling were the pathways most coherently associated with an immune silent phenotype together with mutations of driver genes including IDH1/2, FOXA2, HDAC3, PSIP1, MAP3K1, KRAS, NRAS, EGFR, FGFR3, WNT5A and IRF7. Conclusions This is the first systematic study demonstrating that the prognostic and predictive role of a bona fide favorable intratumoral immune response is dependent on the disposition of specific oncogenic pathways. This information could be used to refine stratification algorithms and prioritize hierarchically relevant targets for combination therapies.

[1]  Chao Cheng,et al.  Systematic Pan-Cancer Analysis Reveals Immune Cell Interactions in the Tumor Microenvironment. , 2017, Cancer research.

[2]  S. Elledge,et al.  Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy , 2017, Science.

[3]  T. Gajewski,et al.  Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity , 2015, Nature.

[4]  M. Ceccarelli,et al.  Disentangling the relationship between tumor genetic programs and immune responsiveness. , 2016, Current opinion in immunology.

[5]  Adrian V. Lee,et al.  An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics , 2018, Cell.

[6]  J. Bergh,et al.  Interactions between immunity, proliferation and molecular subtype in breast cancer prognosis , 2013, Genome Biology.

[7]  F. Marincola,et al.  Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscape. , 2017, European journal of cancer.

[8]  Ben S. Wittner,et al.  Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1 , 2009, Nature.

[9]  P. Bose,et al.  TGF-β-associated extracellular matrix genes link cancer-associated fibroblasts to immune evasion and immunotherapy failure , 2018, Nature Communications.

[10]  J. Sosman,et al.  Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma , 2017, Cell.

[11]  Geoffrey E. Hinton,et al.  Visualizing Data using t-SNE , 2008 .

[12]  Darren J. Burgess,et al.  Spatial transcriptomics coming of age , 2019, Nature Reviews Genetics.

[13]  S. Carter,et al.  Loss of PTEN Is Associated with Resistance to Anti‐PD‐1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma , 2017, Immunity.

[14]  S. Gabriel,et al.  Genomic correlates of response to CTLA-4 blockade in metastatic melanoma , 2015, Science.

[15]  Gordon Li,et al.  History and current state of immunotherapy in glioma and brain metastasis , 2017, Therapeutic advances in medical oncology.

[16]  Sandrine Dudoit,et al.  GC-Content Normalization for RNA-Seq Data , 2011, BMC Bioinformatics.

[17]  G. Getz,et al.  GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers , 2011, Genome Biology.

[18]  L. Chin,et al.  Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade. , 2016, Cancer discovery.

[19]  K. Cibulskis,et al.  Comprehensive analysis of cancer-associated somatic mutations in class I HLA genes , 2015, Nature Biotechnology.

[20]  F. Marincola,et al.  Cancer immune resistance: can theories converge? , 2017, Emerging topics in life sciences.

[21]  V. Miller,et al.  Response to rapamycin analogs but not PD-1 inhibitors in PTEN-mutated metastatic non-small-cell lung cancer with high tumor mutational burden , 2018, Lung Cancer.

[22]  D. Bedognetti,et al.  The MAPK hypothesis: immune-regulatory effects of MAPK-pathway genetic dysregulations and implications for breast cancer immunotherapy , 2017, Emerging topics in life sciences.

[23]  Z. Trajanoski,et al.  Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. , 2013, Immunity.

[24]  G. Freeman,et al.  Orchestration and Prognostic Significance of Immune Checkpoints in the Microenvironment of Primary and Metastatic Renal Cell Cancer , 2015, Clinical Cancer Research.

[25]  J. Lunceford,et al.  IFN-&ggr;–related mRNA profile predicts clinical response to PD-1 blockade , 2017, The Journal of clinical investigation.

[26]  F. Marincola,et al.  Common pathways to tumor rejection , 2013, Annals of the New York Academy of Sciences.

[27]  Emanuel J. V. Gonçalves,et al.  A Landscape of Pharmacogenomic Interactions in Cancer , 2016, Cell.

[28]  S. Varambally,et al.  Inhibition of Hedgehog signaling reprograms the dysfunctional immune microenvironment in breast cancer , 2018, Oncoimmunology.

[29]  R. Rabadán,et al.  Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma , 2019, Nature Medicine.

[30]  F. Marincola,et al.  Transcriptomic profiles conducive to immune-mediated tumor rejection in human breast cancer skin metastases treated with Imiquimod , 2019, Scientific Reports.

[31]  T. Hudson,et al.  Immune oncology, immune responsiveness and the theory of everything , 2018, Journal of Immunotherapy for Cancer.

[32]  F. Marincola,et al.  Prediction of response to anticancer immunotherapy using gene signatures. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  Paul J. Hoover,et al.  Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma , 2018, Cell.

[34]  T. Caliński,et al.  A dendrite method for cluster analysis , 1974 .

[35]  T. Gajewski,et al.  Tumor-intrinsic oncogene pathways mediating immune avoidance , 2015, Oncoimmunology.

[36]  G. Steinberg,et al.  Molecular Drivers of the Non–T-cell-Inflamed Tumor Microenvironment in Urothelial Bladder Cancer , 2016, Cancer Immunology Research.

[37]  Xin Wang,et al.  The immune response‐related mutational signatures and driver genes in non‐small‐cell lung cancer , 2019, Cancer science.

[38]  F. Marincola,et al.  Melanoma NOS1 expression promotes dysfunctional IFN signaling. , 2014, The Journal of clinical investigation.

[39]  T. Chan,et al.  Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab , 2017, Cell.

[40]  Jing Wang,et al.  STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment. , 2016, Cancer research.

[41]  Li Ding,et al.  Scalable Open Science Approach for Mutation Calling of Tumor Exomes Using Multiple Genomic Pipelines. , 2018, Cell systems.

[42]  F. Marincola,et al.  The immunologic constant of rejection. , 2008, Trends in immunology.

[43]  T. Gajewski,et al.  Impact of oncogenic pathways on evasion of antitumour immune responses , 2018, Nature Reviews Cancer.

[44]  C. Sautès-Fridman,et al.  The immune contexture in human tumours: impact on clinical outcome , 2012, Nature Reviews Cancer.

[45]  X. Zhang,et al.  Notch Signaling as a Regulator of the Tumor Immune Response: To Target or Not To Target? , 2018, Front. Immunol..

[46]  F. Marincola,et al.  Pan-cancer adaptive immune resistance as defined by the Tumor Inflammation Signature (TIS): results from The Cancer Genome Atlas (TCGA) , 2018, Journal of Immunotherapy for Cancer.

[47]  Thomas R. Gingeras,et al.  STAR: ultrafast universal RNA-seq aligner , 2013, Bioinform..

[48]  A. McKenna,et al.  Absolute quantification of somatic DNA alterations in human cancer , 2012, Nature Biotechnology.

[49]  Y. Chung,et al.  Immune checkpoint blockade resistance-related B2M hotspot mutations in microsatellite-unstable colorectal carcinoma. , 2019, Pathology, research and practice.

[50]  F. Marincola,et al.  Human melanomas and ovarian cancers overexpressing mechanical barrier molecule genes lack immune signatures and have increased patient mortality risk , 2016, Oncoimmunology.

[51]  Juan Carlos Fernández,et al.  Multiobjective evolutionary algorithms to identify highly autocorrelated areas: the case of spatial distribution in financially compromised farms , 2014, Ann. Oper. Res..

[52]  A. Ballestrero,et al.  Effect of different cytokines on mammaglobin and maspin gene expression in normal leukocytes: possible relevance to the assays for the detection of micrometastatic breast cancer , 2005, British Journal of Cancer.

[53]  J. Mesirov,et al.  The Molecular Signatures Database Hallmark Gene Set Collection , 2015 .

[54]  L. Miller,et al.  Conservation of immune gene signatures in solid tumors and prognostic implications , 2016, BMC Cancer.

[55]  J. Luke,et al.  Density of immunogenic antigens does not explain the presence or absence of the T-cell–inflamed tumor microenvironment in melanoma , 2016, Proceedings of the National Academy of Sciences.

[56]  A. Psyrri,et al.  The emerging role of immunotherapy in head and neck squamous cell carcinoma (HNSCC): anti-tumor immunity and clinical applications. , 2016, Annals of translational medicine.

[57]  F. Marincola,et al.  Gene expression profiling in acute allograft rejection: challenging the immunologic constant of rejection hypothesis , 2011, Journal of Translational Medicine.

[58]  Tae Min Kim,et al.  Genomic landscape associated with potential response to anti-CTLA-4 treatment in cancers , 2017, Nature Communications.

[59]  R. Salgia,et al.  Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations , 2018, Journal of Immunotherapy for Cancer.

[60]  J. Whitsett,et al.  Foxa2 Programs Th2 Cell-Mediated Innate Immunity in the Developing Lung , 2010, The Journal of Immunology.

[61]  N. Hacohen,et al.  Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity , 2015, Cell.

[62]  F. Marincola,et al.  Evolution of Metastases in Space and Time under Immune Selection , 2018, Cell.

[63]  J. McQuade,et al.  Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy. , 2016, Cancer discovery.

[64]  F. Mannavola,et al.  Immune system and melanoma biology: a balance between immunosurveillance and immune escape , 2017, Oncotarget.

[65]  A. Gonzalez-Perez,et al.  A Pan-cancer Landscape of Interactions between Solid Tumors and Infiltrating Immune Cell Populations , 2017, Clinical Cancer Research.

[66]  Jason Townsend.  Editorial Board , 2015, Experimental Gerontology.

[67]  Davide Bedognetti,et al.  Prognostic and predictive immune gene signatures in breast cancer , 2015, Current opinion in oncology.

[68]  R. Calado,et al.  Telomeres in disease , 2012, F1000 medicine reports.

[69]  P. Park,et al.  A molecular portrait of microsatellite instability across multiple cancers , 2016, Nature Communications.

[70]  Jérôme Galon,et al.  The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures. , 2013, Immunity.

[71]  D. Hardie,et al.  AMPK: opposing the metabolic changes in both tumour cells and inflammatory cells? , 2013, Biochemical Society transactions.

[72]  Harry Campbell,et al.  Identification and survival of carriers of mutations in DNA mismatch-repair genes in colon cancer. , 2006, The New England journal of medicine.

[73]  A. Ballestrero,et al.  Schlafen-11 expression is associated with immune signatures and basal-like phenotype in breast cancer , 2019, Breast Cancer Research and Treatment.

[74]  R. Simon,et al.  CXCR3/CCR5 pathways in metastatic melanoma patients treated with adoptive therapy and interleukin-2 , 2013, British Journal of Cancer.

[75]  Guangwei Liu,et al.  FOXA2 promotes the proliferation, migration and invasion, and epithelial mesenchymal transition in colon cancer , 2018, Experimental and therapeutic medicine.

[76]  Ashton C. Berger,et al.  Genomic and Functional Approaches to Understanding Cancer Aneuploidy. , 2018, Cancer cell.

[77]  Peter W. Laird,et al.  Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer , 2018, Cell.

[78]  Guangxu Jin,et al.  Tumor mutational burden is a determinant of immune-mediated survival in breast cancer , 2018, Oncoimmunology.

[79]  H. Zou,et al.  Regularization and variable selection via the elastic net , 2005 .

[80]  T. Gajewski,et al.  Innate immune signaling and regulation in cancer immunotherapy , 2016, Cell Research.

[81]  J. Luke,et al.  WNT/β-catenin Pathway Activation Correlates with Immune Exclusion across Human Cancers , 2019, Clinical Cancer Research.

[82]  Guoping Cai,et al.  Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer. , 2017, Cancer discovery.

[83]  S. Aamdal,et al.  Immune escape of cancer cells with beta2‐microglobulin loss over the course of metastatic melanoma , 2014, International journal of cancer.

[84]  Steven J. M. Jones,et al.  The Immune Landscape of Cancer , 2018, Immunity.

[85]  C. Fan,et al.  Immune-Related Gene Expression Profiling After PD-1 Blockade in Non-Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and Melanoma. , 2017, Cancer research.

[86]  J. Locasale,et al.  Paracrine Wnt5a‐&bgr;‐Catenin Signaling Triggers a Metabolic Program that Drives Dendritic Cell Tolerization , 2018, Immunity.

[87]  F. Marincola,et al.  Immunogenic Subtypes of Breast Cancer Delineated by Gene Classifiers of Immune Responsiveness , 2016, Cancer Immunology Research.

[88]  J. L. Holloway,et al.  Genome-wide association analysis identifies genetic correlates of immune infiltrates in solid tumors , 2017, bioRxiv.

[89]  Joseph F. Murphy,et al.  Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop , 2019, Journal of Immunotherapy for Cancer.

[90]  Nir Hacohen,et al.  Resistance to checkpoint blockade therapy through inactivation of antigen presentation , 2017, Nature Communications.

[91]  F. Marincola,et al.  Immunogenomic Classification of Colorectal Cancer and Therapeutic Implications , 2017, International journal of molecular sciences.

[92]  F. Marincola,et al.  Identification of genetic determinants of breast cancer immune phenotypes by integrative genome-scale analysis , 2017, Oncoimmunology.

[93]  Zlatko Trajanoski,et al.  Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade , 2016, bioRxiv.

[94]  F. Marincola,et al.  The immunologic constant of rejection classification refines the prognostic value of conventional prognostic signatures in breast cancer , 2018, British Journal of Cancer.